773134-43-3

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-bromo-2-(methylsulfonyl)benzoate is used as a key intermediate in the synthesis of Alkynylphenoxyacetic Acid CRTH2 (DP2) Receptor Antagonists. These antagonists are designed for the treatment of allergic inflammatory diseases, such as asthma and allergic rhinitis. methyl 4-bromo-2-(methylsulfonyl)benzoate's presence in the synthesis process contributes to the development of effective therapeutic agents that can modulate the immune response and alleviate symptoms associated with these conditions.
In the synthesis of Alkynylphenoxyacetic Acid CRTH2 (DP2) Receptor Antagonists, methyl 4-bromo-2-(methylsulfonyl)benzoate plays a crucial role due to its ability to undergo various chemical transformations, such as cross-coupling reactions, nucleophilic substitutions, and functional group interconversions. These reactions allow for the introduction of diverse functional groups and structural motifs, which can be tailored to optimize the pharmacological properties of the resulting antagonists.
Furthermore, the use of methyl 4-bromo-2-(methylsulfonyl)benzoate in the synthesis of CRTH2 antagonists highlights its potential as a versatile building block in the development of novel therapeutic agents. Its unique structural features and reactivity make it an attractive candidate for the design and synthesis of new drugs targeting various biological pathways and disease states.

Upstream product

• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 20776-50-5 2-amino-4-bromobenzoic acid 
• 116209-30-4 4-bromo-2-mercaptobenzoic acid 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 
• 67-56-1 methanol 

Downstream Products

• 1240288-81-6 6-bromo-1-benzothiophen-3(2H)-one 1,1-dioxide 
• 773873-27-1 (4-bromo-2-(methylsulfonyl)phenyl)methanol 

Relevant academic research and scientific papers

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS

The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I): whe

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

PIPERAZINE DERIVATIVES AS LIVER X RECEPTOR MODULATORS

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver X receptor. Also provided are the compounds of Formula (I) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, Alzheimer's disease, dermatitis, dyslipidemia, cancer and other diseases or disorders.

NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE

Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.

Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases

New phenoxyacetic acid antagonists of CRTH2 are described. Following the discovery of a hit compound by a focused screening, high protein binding was identified as its main weakness. Optimization aimed at reducing serum protein binding led to the identification of several compounds that showed not only excellent affinities for the receptor (41 compounds with Ki 50 100 nM; PGD2-induced eosinophil shape change). Additional optimization of the PK characteristics led to the identification of several compounds suitable for in vivo testing. Of these, 19k and 19s were tested in two different pharmacological models (acute FITC-mediated contact hypersensitivity and ovalbumin-induced eosinophilia models) and found to be active after oral dosing (10 and 30 mg/kg).

PHENOXY ACETIC ACID DERIVATIVES

The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.